ERBB3 and neoplasm: Assuming that optimal therapeutic activity of mAbs requires tumor accumulation and saturation of target receptor binding, an understanding of the tumor-targeting capabilities of GSK2849330 and its interaction with the HER3 receptor would help identify an optimal dose sufficient to fully saturate tumor HER3 receptors and block HER3-mediated signaling.